The Global Health Body Issues Alert Over Critical Scarcity of Obesity Jabs

Less than one in 10 individuals eligible to benefit from obesity jabs including Wegovy have access to them, states the global health agency as it releases its initial advice on the therapies.

Given in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.

According to estimates, more than two billion could be living with obesity by 2030 without intervention.

"The new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and continuous support," said WHO director-general Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and logistical bottlenecks are major obstacles to widespread access to the treatments that can help people shift significant body mass, says the agency.

Skinny Jab Supply Crisis

Even under the current most favorable case, the production of such drugs would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The advice urges countries and companies to expand availability, via approaches such as patent sharing.

Exclusive production rights on semaglutide – the primary component of a leading brand – is scheduled to end in multiple nations in 2026.

The Way Weight-Loss Drugs Operate

GLP-1 drugs imitate a body's own hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals consume fewer calories.

Patients usually see weight reduction within a few weeks of starting on the weekly injections.

Research suggests users may see weight return within a year of halting the medication, when their normal hunger come back.

Being above a healthy weight increases your likelihood for experiencing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Obesity affects individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the health agency.